Fibrin Sealant (FS) VH S/D 500 s-apr
DrugDosage form: spray application; dosage frequency: single application
Other names: Tisseel
NCT Number: NCT01244425
The purpose of the study is to compare safety and efficacy of Fibrin Sealant (FS) Vapor Heated (VH) S/D 500 s-apr with manual compression as a supportive treatment of local bleeding (i.e. oozing) in hepatic resection surgery when standard surgical techniques are insufficient.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Berlin, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Pre-Operative Inclusion Criteria:
Intra-Operative Inclusion Criteria (before randomization):
Pre-Operative Exclusion Criteria:
Intra-operative Exclusion Criteria (before randomization):
Dosage form: spray application; dosage frequency: single application
Other names: Tisseel
Dosage form: surgical gauze swab; dosage frequency: single application
Time frame: 4 minutes post start of treatment application
Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.
The following were regarded as treatment failures:
Time frame: 6 minutes after start of treatment application
Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.
Time frame: 8 minutes after start of treatment application
Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.
Time frame: 10 minutes after start of treatment application
Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.
Time frame: Intraoperative day 0
Intraoperative rebleeding from the treated liver resection surface after occurrence of hemostasis.
Time frame: Postoperative until discharged from surgical ward
Rebleeding until discharged from the surgical ward, defined as any rebleeding from the treated liver resection surface requiring surgical reexploration
Time frame: Intra- and postoperative until discharged from surgical ward
Transfusions administered included whole blood, packed red blood cells, fresh frozen plasma, and thrombocyte concentrate.
Time frame: Within 48 hours after surgery
Baxter Healthcare Corporation
Industry
A Randomized, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fibrin Sealant VH S/D 500 S-apr (Tisseel) for Hemostasis in Subjects Undergoing Hepatic Resection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737366
Anxiety, Anxiety Disorders
Sakarya, Turkey (Türkiye)
View Trial DetailsNCT06095518
Cardiovascular Diseases, Embolism and Thrombosis
Hong Kong
View Trial DetailsNCT06192836
Cesarean Section Complications, Dystocia
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07352761
Blood Loss, Surgical, Hemorrhage
Alexandria, El-Shatby, Egypt
View Trial Details